Skip to main content
. 2019 Dec 10;21(1):e8. doi: 10.4142/jvs.2020.21.e8

Table 3. Number of post-operative complications, n. and doses of post-operative administration of labetalol, dexmedetomidine and acepromazine.

Information recorded Sevo-Op Sevo-Dex p value Sevo-Op vs. Sevo-Dex
OR (95% CI) p value
Postoperative complications (No.) 4 Bradycardia 10 Bradycardia 0.35 3.33 (0.50–22.14) 0.21
1 Tachycardia 2 Tachycardia 0.99 1.27 (0.096–16.81) 0.85
3 Hypertension 8 Hypertension 0.39 2.67 (0.43–16.40) 0.29
4 Agitation 8 Agitation 0.67 1.6 (0.27–9.49) 0.60
0 Seizures 1 Seizures 0.99 2.0 (0.074–56.27) 0.67
2 Hypothermia 8 Hypothermia 0.18 4.8 (0.68–33.8) 0.12
0 Hyperthermia 2 Hyperthermia 0.50 3.7 (0.16–87.39) 0.42
Postoperative labetalol administration (No.) [(dose in mg/kg/h)] 2 [1.75 (1.5–2)] 6 [1.9 (1.3–2.4)] 0.40 2.57 (0.37–17.83) 0.34
Postoperative dexmedetomidine administration (No.) [(dose in µg/kg/min)] 7 [0.015 (0.008–0.025)] 13 [0.011 (0.005–0.023)] 0.38 5.4 (0.19–149.79) 0.32
Reason for postoperative dexmedetomidine (No.) 6 Preemptive 13 Preemptive 0.35 - -
1 Reactive 0 Reactive
Postoperative acepromazine administration (No.) [(dose in µg/kg)] 5 [8.8 (5–10)] 9 [10.4 (7–20)] 0.99 1.35 (0.21–8.62) 0.75

OR and 95% CI are reported. The p values, unless otherwise stated, correspond to statistical test comparing number of animals receiving treatment rather than the dose.

OR, odds ration; CI, confidence interval; Group Sevo-Op, sevoflurane and short acting opioid infusion; Group Sevo-Dex, sevoflurane and dexmedetomidine infusion.